| Literature DB >> 19603029 |
H Iijima1, H B Patrzyc, E E Budzinski, H G Freund, J B Dawidzik, K J Rodabaugh, H C Box.
Abstract
BACKGROUND: A long-standing hypothesis is that oxidative stress is a risk factor for cancer. Support for this hypothesis comes from observations of higher levels of oxidative damage in the DNA of WBC of cancer patients compared with healthy controls.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19603029 PMCID: PMC2720235 DOI: 10.1038/sj.bjc.6605176
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1Forms of the formamide (A) and thymine glycol (B) modifications, measured by LC-MS/MS.
Figure 2LC-MS/MS elution profiles of the formamide and thymine glycol modifications obtained from the DNA of untreated WBC from a healthy donor. The second trace in each example is from the internal standard, which serves to quantify the measurement.
Levels of formamide and thymine glycol lesions in WBC compared with levels in WBC exposed to 500 Gy X-ray or 250 J m−2 UVC
|
|
| |
|---|---|---|
| Samples (5), control | 4.89±0.76 | 2.23±0.34 |
| Samples (5), 500 Gy | 5.37±1 02 | 5.69±1.02 |
| Samples (8), control | 5.76±0.75 | 4.48±1.01 |
| Samples (8), 250 J m−2 | 14.6±2.08 | 8.41±1.36 |
Values are given in femtomoles of lesion per microgram of DNA.
Numbers in parentheses indicate the number of donors; error measures are standard errors of the mean.
Levels of the formamide and thymine glycol modifications in WBC of ovarian cancer patients and healthy controls
|
|
| |
|---|---|---|
| Ovarian cancer patients (19) | 6.38±0.83 | 2.83±0.45 |
| Controls (16) | 5.56±0.86 | 2.16±0.38 |
Values are given in femtomoles of lesion per microgram of DNA.
Numbers in parentheses indicate the number of donors; error measures are standard errors of the mean.
Figure 3Range and distribution of ages of case and control participants plotted against d(PfpA) levels.
Figure 4Range and distribution of ages of case and control participants plotted against d(TgpA) levels.
Oxidative DNA damage in cancer and control groups
|
|
|
|
|
|
|---|---|---|---|---|
| Lung cancer, dGh/106N | 7.30±1.12 (48) | 11.6±1.54 (46) | +59 |
|
| Leukemia, dGh/106N | 8.52±0.55 (11) | 13.6±0.72 (22) | +60 |
|
| Colorectal cancer, dGh/106N | 1.91±0.13 (35) | 2.74±0.23 (36) | +43 |
|
| Bladder cancer, dGh/106N | 4.36±0.19 (22) | 7.52±0.58 (29) | +71 |
|
| Breast cancer, dGh/106N | 121±18 (32) | 278±29 (29) | +128 |
|
| Oesophagial cancer, dGh/106N | 0.98±0.06 (43) | 1.44±0.12 (17) | +46 |
|
| Ovarian cancer, dPf/106N | 5.63±0.87(15) | 6.43±0.84(19) | +14 | This report |
| Ovarian cancer, dTg/106N | 2.16±0.38(15) | 2.83±0.45(19) | +31 | This report |
Measurements of 8-oxo-7,8-dihydroguanine , formamide and thymine glycol modifications in cancer and control groups.
Values are dGh/106N, dPf/106N or dTg/106N±s.e.m.; numbers in parentheses indicate the number of participants.